LINKThis experimental treatment uses antibodies from the serum (the fluid portion of blood) of goats that have been inoculated with a variety of vaccines, to generate neutralizing antibodies. Antibodies are proteins produced by white blood cells in response to an antigen (foreign protein), to destroy/neutralize the antigen. The anti-inflammatory component of the serum is thought by researchers to be ‘potentially useful’ in the treatment of MS.

Daval International was cited for misleading advertising about Aimspro on its Web site in July 2004 by the UK Medicines and Healthcare Products Regulatory Agency, and the company responded by removing most of its claims for the product.

Evidence:
There is no research evidence or published information available to back up the anecdotal claims about goat serum.

Some individuals with MS in the United Kingdom had received goat serum outside of clinical trials through a program of informed consent from general practitioners. This program is no longer available, and no more people can receive this drug via informed consent.

Clinical trials:

A controlled trial (where half of the participants are receiving the treatment and half are on placebo (a dummy treatment) was begun St. George's Hospital in South London. Eighty participants with secondary-progressive MS are involved. A March 2, 2005 announcement by the manufacturer stated that this trial has been halted. No further information is available at this time.

Another clinical trial of Aimspro was conducted in Oxford in an unknown number of persons with optic neuritis. Results have not been published in a peer-reviewed medical journal.
 
Availability:
This drug is not available to the general public.